Techcyte tops 11 million AI-assisted scans on global diagnostics platform

Techcyte says its platform has now processed more than 11 million AI-assisted scans across human, veterinary and environmental diagnostic workflows. The milestone underscores growing demand for digital pathology tools as labs face staffing shortages and more testing moves online.

Why it matters: - Techcyte’s milestone signals wider adoption of AI-assisted pathology and diagnostics across laboratories, clinics and environmental testing workflows. - The company is pitching its platform as a way to ease the global shortage of microscopy experts without replacing them. - The scale of use across humans, animals and the environment gives Techcyte a broader footprint than a single-discipline diagnostics tool.

What happened: - Techcyte announced it has surpassed 11 million AI-assisted scans processed across active customer environments worldwide. - The scans span human, veterinary and environmental diagnostic platforms. - The announcement was made July 21, 2026, from Orem, Utah. - Techcyte said its platform is used by more than 10,000 customers in over 40 countries.

The details: - Techcyte’s platform covers anatomic pathology, bacteriology, parasitology, hematology, cytology, veterinary diagnostics, mold and indoor air quality analysis, and rapid microbial detection for food safety. - CEO Ben Cahoon said the 11 million-scan mark reflects customer trust and the work of the Techcyte team. - Techcyte says it built the first and only platform to unify anatomic and clinical pathology. - The company says its deep learning image analysis and workflow platform is designed to improve accuracy and efficiency in laboratories. - Techcyte’s collaboration with Zoetis produced Vetscan Imagyst, a seven-in-one AI-assisted veterinary diagnostic solution now used in practices worldwide. - Research-use-only deployments include ARUP Laboratories, Cleveland Clinic, Mayo Clinic, Northwest Arkansas Pathology Associates, Tyrolpath and Quest Diagnostics. - Sporecyte, Techcyte’s AI tool for mold and indoor air quality analysis, is described by the company as the only platform of its kind. - Techcyte was founded in 2013. - The company’s platform is for Research Use Only in the United States. - Techcyte said it partners with labs, slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers and solution providers. - More information is available on Techcyte’s website.

Between the lines: - The milestone is also a signal that AI in diagnostics is moving from pilot projects into routine workflow use. - Techcyte is positioning itself around workflow support, not automation that replaces specialists, which may help adoption in a workforce-constrained market. - The company’s emphasis on human, animal and environmental testing suggests a strategy to spread risk across multiple diagnostics sectors.

What's next: - Techcyte said it plans to expand AI capabilities and enter new microscopy-based testing markets. - The company also wants to reach more laboratories and clinics that have not yet shifted to digital workflows. - Future growth appears tied to deeper penetration in existing markets and broader adoption of digital pathology infrastructure.